Multiple sclerosis (MS) is an immune-mediated inflammatory disease of the central nervous system. B cells have been strongly implicated in disease pathogenesis based on clinical trials with B-cell ablation. There is a growing body of evidence linking microRNAs with regulation of the immune system. Dicer, a key enzyme involved in microRNA biogenesis, is necessary for normal B-cell function.
Objective:
We aimed to determine whether Dicer expression is impaired in B cells and is linked to increased expression co-stimulatory molecules in patients with MS.
Methods:
B cells were separated from blood samples of MS patients and healthy subjects. Expression of Dicer and co-stimulatory molecules CD80 and CD86 was tested. The effect of Dicer modulation on CD80 and CD86 expression in B cells was studied.
Results:
Dicer expression was decreased in B cells but not in monocytes of patients with MS compared with healthy subjects. CD80 and CD86 expression was increased on B cells of MS patients compared with healthy subjects. Inhibition of Dicer expression in B cells by small interfering RNA led to increased expression of CD80.
Conclusion:
Dicer expression is decreased and is mechanistically linked to increased expression of co-stimulatory molecule CD80 in B cells of patients with MS. This may contribute to activation of immune responses in MS.
KuenzBLutterottiAEhlingR. Cerebrospinal fluid B cells correlate with early brain inflammation in multiple sclerosis. PLoS One2008; 3: e2559.
2.
FranciottaDSalvettiMLolliF. B cells and multiple sclerosis. Lancet Neurol2008; 7: 852–858.
3.
CrossAHWaubantE.MS and the B cell controversy. Biochim Biophys Acta2011; 1812: 231–238.
4.
Bar-OrACalabresiPAArnoldD. Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial. Ann Neurol2008; 63: 395–400.
5.
HauserSLWaubantEArnoldDL. B-cell depletion with rituximab in relapsing–remitting multiple sclerosis. N Engl J Med2008; 358: 676–688.
6.
KapposLLiDCalabresiPA. Ocrelizumab in relapsing–remitting multiple sclerosis: A phase 2, randomised, placebo-controlled, multicentre trial. Lancet2011; 378: 1779–1787.
7.
NaismithRTPiccioLLyonsJA. Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: A 52-week phase II trial. Neurology2010; 74: 1860–1867.
8.
Bar-OrAFawazLFanB. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?Ann Neurol2010; 67: 452–461.
9.
BouazizJDCalboSMaho-VaillantM. IL-10 produced by activated human B cells regulates CD4(+) T-cell activation in vitro. Eur J Immunol2010; 40: 2686–2691.
10.
ThompsonCBLindstenTLedbetterJA. CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. Proc Natl Acad Sci U S A1989; 86: 1333–1337.
HarpCTIrelandSDavisLS. Memory B cells from a subset of treatment-naive relapsing-remitting multiple sclerosis patients elicit CD4(+) T-cell proliferation and IFN-gamma production in response to myelin basic protein and myelin oligodendrocyte glycoprotein. Eur J Immunol2010; 40: 2942–2956.
13.
GoodKLAveryDTTangyeSG.Resting human memory B cells are intrinsically programmed for enhanced survival and responsiveness to diverse stimuli compared to naive B cells. J Immunol2009; 182: 890–901.
14.
Bar-OrAOliveiraEMAndersonDE. Immunological memory: contribution of memory B cells expressing costimulatory molecules in the resting state. J Immunol2001; 167: 5669–5677.
15.
GencKDonaDLRederAT.Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy. J Clin Invest1997; 99: 2664–2671.
16.
KrolJLoedigeIFilipowiczW.The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet2010; 11: 597–610.
17.
BartelDP.MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell2004; 116: 281–297.
18.
O’ConnellRMRaoDSChaudhuriAA. Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immunol2010; 10: 111–122.
19.
KoralovSBMuljoSAGallerGR. Dicer ablation affects antibody diversity and cell survival in the B lymphocyte lineage. Cell2008; 132: 860–874.
20.
BelverLde YebenesVGRamiroAR.MicroRNAs prevent the generation of autoreactive antibodies. Immunity2010; 33: 713–722.
21.
PolmanCHReingoldSCBanwellB. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Ann Neurol2011; 69: 292–302.
22.
JacobsLDBeckRWSimonJH. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med2000; 343: 898–904.
23.
KurtzkeJF.Rating neurologic impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS). Neurology1983; 33: 1444–1452.
24.
BalashovKEAungLLVaknin-DembinskyA. Interferon-beta inhibits toll-like receptor 9 processing in multiple sclerosis. Ann Neurol2010; 68: 899–906.
25.
WindhagenANewcombeJDangondF. Expression of costimulatory molecules B7–1 (CD80), B7–2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J Exp Med1995; 182: 1985–1996.
26.
SvenningssonADotevallLStemmeS. Increased expression of B7–1 costimulatory molecule on cerebrospinal fluid cells of patients with multiple sclerosis and infectious central nervous system disease. J Neuroimmunol1997; 75: 59–68.
27.
LinsleyPSLedbetterJA.The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol1993; 11: 191–212.
28.
GimmiCDFreemanGJGribbenJG. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc Natl Acad Sci U S A1993; 90: 6586–6590.
29.
KuchrooVKDasMPBrownJA. B7–1 and B7–2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: Application to autoimmune disease therapy. Cell1995; 80: 707–718.
30.
LumsdenJMWilliamsJAHodesRJ.Differential requirements for expression of CD80/86 and CD40 on B cells for T-dependent antibody responses in vivo. J Immunol2003; 170: 781–787.
31.
HanLZhangAZhouX. Downregulation of Dicer enhances tumor cell proliferation and invasion. Int J Oncol2010; 37: 299–305.
32.
LeppertDLindbergRLKapposL. Matrix metalloproteinases: Multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis. Brain Res Brain Res Rev2001; 36: 249–257.
33.
LevyCKhaledMRobinsonKC. Lineage-specific transcriptional regulation of DICER by MITF in melanocytes. Cell2010; 141: 994–1005.
